Paper39713985
Targeting undruggable protein KRAS for cancer therapy: novel opportunities and challenges.
Yang X and 8 others. Future Med Chem, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Targeting undruggable protein KRAS for cancer therapy: novel opportunities and challenges. Papers, record 39713985. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39713985
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Targeting undruggable protein KRAS for cancer therapy: novel opportunities and challenges.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References27
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38637634 | Targeting KRAS in cancer. | Nat Med | 2024 | https://conductscience.org/library/papers/38637634 | PubMed |
| 2 | 3915535 | ras gene Amplification and malignant transformation. | Mol Cell Biol | 1985 | https://conductscience.org/library/papers/3915535 | PubMed |
| 3 | 35046095 | Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. | Cancer Discov | 2022 | https://conductscience.org/library/papers/35046095 | PubMed |
| 4 | 38924388 | Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRASG12C Inhibitor. | J Med Chem | 2024 | https://conductscience.org/library/papers/38924388 | PubMed |
| 5 | 31666701 | The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. | Nature | 2019 | https://conductscience.org/library/papers/31666701 | PubMed |
| 6 | 34680208 | Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34680208 | PubMed |
| 7 | 36849761 | Inhibition mechanism of MRTX1133 on KRASG12D: a molecular dynamics simulation and Markov state model study. | J Comput Aided Mol Des | 2023 | https://conductscience.org/library/papers/36849761 | PubMed |
| 8 | 39298590 | Targeting cancer with small-molecule pan-KRAS degraders. | Science | 2024 | https://conductscience.org/library/papers/39298590 | PubMed |
| 9 | 24256730 | K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. | Nature | 2013 | https://conductscience.org/library/papers/24256730 | PubMed |
| 10 | 38236605 | Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers. | Cancer Discov | 2024 | https://conductscience.org/library/papers/38236605 | PubMed |
| 11 | 38009264 | Progress in RAS-targeted therapeutic strategies: From small molecule inhibitors to proteolysis targeting chimeras. | Med Res Rev | 2024 | https://conductscience.org/library/papers/38009264 | PubMed |
| 12 | 36546659 | Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. | N Engl J Med | 2023 | https://conductscience.org/library/papers/36546659 | PubMed |
| 13 | 37870968 | Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. | N Engl J Med | 2023 | https://conductscience.org/library/papers/37870968 | PubMed |
| 14 | 37395055 | Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRASG12C with Demonstrable CNS Penetration. | J Med Chem | 2023 | https://conductscience.org/library/papers/37395055 | PubMed |
| 15 | 37729426 | Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy. | Cancer Res | 2023 | https://conductscience.org/library/papers/37729426 | PubMed |
| 16 | 27338794 | A combinatorial strategy for treating KRAS-mutant lung cancer. | Nature | 2016 | https://conductscience.org/library/papers/27338794 | PubMed |
| 17 | 30481508 | Clinical validation of coexisting driver mutations in colorectal cancers. | Hum Pathol | 2019 | https://conductscience.org/library/papers/30481508 | PubMed |
| 18 | 34365406 | KRAS Inhibitor Resistance in MET-Amplified KRAS G12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/34365406 | PubMed |
| 19 | 35101229 | Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone. | Adv Cancer Res | 2022 | https://conductscience.org/library/papers/35101229 | PubMed |
| 20 | 37921024 | Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido[4,3-d]pyrimidine Analogues Bearing Deuterated Methylene Linkers as Potent KRASG12D Inhibitors. | J Med Chem | 2023 | https://conductscience.org/library/papers/37921024 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| KRAS | 3845 | PubTator's text mining | https://conductscience.org/library/genes/3845 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39713985
GET https://conductscience.org/api/papers/v1/39713985/references?page=2